Crossmark

Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration

Crossref DOI link: https://doi.org/10.1186/s12885-025-14286-7

Published Online: 2025-05-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Mengwei

Bai, Long

Chen, Jianwen

Meng, Qi

Lu, Yunxin

Zhang, Dongsheng
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82002465, 82172711)

Natural Science Foundation of Guangdong Province (2019A1515011786)
License Information

Text and Data Mining valid from 2025-05-24

Version of Record valid from 2025-05-24
More Information

Article History

Received: 8 February 2024

Accepted: 7 May 2025

First Online: 24 May 2025

Declarations

:

: This was a non-interventional and retrospective study in which the patient data used were kept strictly confidential. The retrospective study was approved by the Ethical Committee of Sun Yat-sen University Cancer Center (protocol code B2023-048–01, approved on 17 February 2023). Informed consent was waived by the Ethical Committee.

: All authors have read and approved the final version to be published.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below